Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > Last calendar about rescheduling from 1 to 3
View:
Post by subaru1 on Jul 08, 2024 12:16pm

Last calendar about rescheduling from 1 to 3

Timeline for Implementation

Key dates include:

  • May 21, 2024: Publication of the proposed rescheduling draft ruling (PRDR) in the Federal Register and the start of a 60-day public comment period.
  • June 21, 2024: Deadline for interested parties to request a hearing.
  • July 20, 2024: End of the public comment period.
  • August 20, 2024 (or September 20, 2024): Expected publication of the final ruling. The final ruling becomes effective 30 days after publication, potentially around September 20, 2024.

Potential Risks And Wild Cards

Zuanic identifies several wild cards that could influence the process and outcomes:

  • Scope of Cole Memo II: Whether it includes SAFE banking language, provides a safe harbor for U.S. exchanges to list plant-touching stocks, and addresses FinCEN-related matters.
  • Legal Challenges: Judicial challenges are expected, but legal scholar Shane Pennington considers a stay unlikely.
  • Political Factors: Statements from Donald Trump and their impact on public opinion.

Sector And Stock Impacts

The rescheduling news has broader implications for the cannabis sector.

Canadian licensed producers (LPs) like Canopy Growth Corporation (NASDAQ:CGC) and SNDL (NASDAQ:SNDL) might need to form partnerships with U.S. companies to capitalize on the changing landscape.

 
 

 

Companies such as Tilray Brands (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), and others are under scrutiny for their strategic moves in response to the evolving regulatory environment.

Comment by subaru1 on Jul 10, 2024 2:54pm
Congressional vote to block cannabis rescheduling (Newsletter: July 10, 2024) Published   on  July 10, 2024
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities